Recruiting Clinical Trials

Displaying 11 - 20 of 213 result(s)
Study Title Condition Phase Location
Open-Label Rater-Blind Randomized Multi-Center Parallel-Arm Active- Comparator Study to Assess the Efficacy and Tolerability of Ofatumumab 20mg SC Monthly vs. First Line DMT - Physician's Choice in the Treatment of Newly Diagnosed RMS Multiple Sclerosis Phase 3
  • Country: 
    France
  • Country: 
    Germany
  • Country: 
    Spain
A Phase II, Open Label, Randomized, Parallel Arm Study of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy Gemcitabine/Nab-paclitaxel, and Gemcitabine/Nab-paclitaxel Alone in First-line Metastatic Pancreatic Ductal Adenoca ... Metastatic Pancreatic Ductal Adenocarcinoma Phase 2
  • Country: 
    United States
  • Country: 
    Australia
  • Country: 
    Austria
  • Country: 
Special Drug Use Surveillance for Entresto Tablets (Chronic Heart Failure, CLCZ696B1401) Chronic Heart Failure Not Given
  • Country: 
    Japan
Phase III Study for Evaluation of the Diagnostic Performance of [18F]CTT1057 PET Imaging in Patients With Prostate Cancer With Rising PSA Levels [Biochemical Recurrence (BCR)] Prostatic Neoplasms, Prostate Cancer, Recurrence Phase 3
  • Country: 
    France
  • Country: 
    Spain
A Randomized, Subject and Investigator Blinded, Placebo-controlled Multicenter Study to Assess the Efficacy and Safety of CMK389 in Patients With Moderate to Severe Atopic Dermatitis Atopic Dermatitis Phase 2
  • Country: 
    Czech Republic
  • Country: 
    Germany
  • Country: 
    Hungary
  • Country: 
A Phase I/Ib, Open-label, Multi-center Study of DFF332 as a Single Agent and in Combination With Everolimus or IO Agents in Patients With Advanced/Relapsed ccRCC and Other Malignancies With HIF2α Stabilizing Mutations Carcinoma, Renal Cell Phase 1
  • Country: 
    Japan
Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients (Prevention of Relapses and Delay of Progression of Physical Disability in Secondary Progressive Multiple Sclerosis) Secondary Progressive Multiple Sclerosis (SPMS) Not Given
  • Country: 
    Japan
A 12-week Randomized, participant-and Investigator-blinded, Placebo-controlled, Parallel Group Study to Explore the Efficacy, Pharmacodynamics, Safety, and Pharmacokinetics of Two Doses of Inhaled CSJ117 in Adults With Chronic Obstructive Pulmonary D ... Pulmonary Disease, Chronic Obstructive Phase 2
  • Country: 
    United States
  • Country: 
    Australia
  • Country: 
    Hungary
An Indian Multi-centric Phase IV Study to Assess the Safety of Crizanlizumab With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Vaso-occlusive Crises. Sickle Cell Disease (SCD) Phase 4
  • Country: 
    India
A 24-week, Multicenter, Randomized, Double-blind, Parallel-arm, Placebo-controlled Extension Study to Assess the Safety of CSJ117, When Added to Existing Standard of Care Asthma Therapy in Patients ≥18 Years of Age Asthma Phase 2
  • Country: 
    United States
  • Country: 
    Czech Republic
  • Country: 
    Hungary
  • Country: